Clinical Trials Training and Resources

Browse SITC programs focused on the unique challenges of cancer immunotherapy clinical trials.

Featured Program

SITC) Clinical Immuno-Oncology Network (SCION) Workshop

SCION is an intimate immunotherapy clinical trial development program, led by experts in the field who are equipped to help their assigned students navigate through the unique considerations that accompany immunotherapy treatments.

Explore SCION

SCION Logo

SITC Clinical Immuno-Oncology Network

Designed to address the unique considerations for designing clinical trial protocols focused on cancer immunotherapy, the SCION Workshop connects participants with experienced faculty in the field and dedicated patient advocates to advise on clinical trial protocol development.

Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC)

Phase III trials are how new treatments for cancer demonstrate benefit and establish their place in the treatment paradigm to offer improved outcomes for patients. These trials are time- and resource-intensive, involving hundreds of patients and spanning multiple years. As many as half of phase III trials in oncology are unsuccessful, representing substantial losses in terms of monetary investment and opportunity for patients to receive a more effective treatment for their disease.

SITC Publishes Consensus Definitions for Immune Checkpoint Inhibitor-Related Adverse Events Terminology

Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of several solid tumors, providing deep and durable responses for many patients. However, the anti-tumor mechanism of action of ICIs can also cause aberrantly active self-damaging immune responses, leading to immune-related adverse events (irAEs). The natural history, response to treatment, and patterns of irAEs vary widely, ranging from short-term inflammatory conditions to prolonged inflammation and damage to organs leading to permanent dysfunction.

Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations from the Society for Immunotherapy of Cancer & the International Bladder Cancer Group

On behalf of the Society for Immunotherapy of Cancer (SITC) and the International Bladder Cancer Group (IBCG), we are pleased to announce the publication of the “Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group,” in the Journal of Clinical Oncology. 

SITC Recommendations on Intratumoral Immunotherapy Clinical Trial (IICT) Design

On behalf of the society and the SITC Intratumoral Immunotherapy Clinical Trials Manuscript Development Group, we are pleased to announce the publication of a new manuscript “Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from pre-malignant to metastatic disease” in the Journal for ImmunoTherapy of Cancer.